Treatment-related Neuroendocrine Prostate Carcinoma-Diagnostic and Molecular Correlates
1Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract:
Treatment-related neuroendocrine prostate cancer is a distinctive category of prostate cancer that arises after intensive suppression of the androgen receptor by next-generation therapeutic inhibition of androgen receptor signaling. The biological processes that set in motion the series of events resulting in transformation of adenocarcinoma to neuroendocrine carcinoma include genomic (loss of tumor suppressors TP53 and RB1, amplification of oncogenes N-MYC and Aurora Kinase A, dysregulation of transcription factors SOX2, achaete-scute-homolog 1, and others) as well as epigenomic (DNA methylation, EZH2 overexpression, and others). Pathologic diagnosis is key to effective therapy for this disease, and this is aided by localizing metastatic lesions for biopsy using radioligand imaging in the appropriate clinical context. As our understanding of biology evolves, there has been increased morphologic recognition and characterization of tumor phenotypes that are present in this advanced post-treatment setting. New and promising biomarkers (delta-like ligand 3 and others) have been discovered, which opens up novel therapeutic avenues including immunotherapy and antibody-drug conjugates for this lethal disease with currently limited treatment options.
Insights
Treatment-related neuroendocrine prostate cancer develops after intensive androgen receptor signaling inhibition. Genomic and epigenomic changes drive this transformation, necessitating advanced diagnostics and novel biomarkers for effective treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Treatment-related neuroendocrine prostate cancer (t-NEPC) is a distinct subtype arising after androgen receptor signaling inhibition (ARSI).
- Adenocarcinoma transforms into neuroendocrine carcinoma due to genomic alterations like TP53/RB1 loss and N-MYC amplification, alongside epigenomic changes such as DNA methylation and EZH2 overexpression.
- Morphological characterization of tumor phenotypes in this advanced post-treatment setting is evolving.
Purpose of the Study:
- To elucidate the biological mechanisms underlying the transformation of prostate adenocarcinoma to neuroendocrine carcinoma following intensive ARSI.
- To highlight the importance of accurate pathologic diagnosis and the role of radioligand imaging in identifying metastatic lesions for biopsy.
- To introduce novel biomarkers and therapeutic avenues for advanced t-NEPC.
Main Methods:
- Analysis of genomic alterations (TP53, RB1, N-MYC, Aurora Kinase A) and epigenomic dysregulation (SOX2, achaete-scute-homolog 1, DNA methylation, EZH2).
- Utilizing radioligand imaging for metastatic lesion localization to guide biopsy.
- Morphological characterization of advanced post-treatment tumor phenotypes.
Main Results:
- Identified key genomic drivers including loss of TP53 and RB1, and amplification of N-MYC and Aurora Kinase A.
- Observed epigenomic alterations involving DNA methylation and EZH2 overexpression.
- Discovered promising biomarkers such as delta-like ligand 3 (DLL3).
Conclusions:
- Understanding the genomic and epigenomic landscape is crucial for diagnosing and treating t-NEPC.
- Radioligand imaging aids in precise diagnosis and biopsy of metastatic sites.
- Emerging biomarkers like DLL3 offer new therapeutic possibilities, including immunotherapy and antibody-drug conjugates, for this aggressive cancer with limited options.
More Related Videos
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018